Advertisement
Advertisement

LCTX

LCTX logo

Lineage Cell Therapeutics, Inc.

1.03
USD
Sponsored
0.00
+0.49%
Jul 27, 13:57 UTC -4
Open

LCTX Earnings Reports

Positive Surprise Ratio

LCTX beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$4.11M
/
-$0.02
Implied change from Q1 26 (Revenue/ EPS)
+138.34%
/
-33.33%
Implied change from Q2 25 (Revenue/ EPS)
+48.70%
/
-71.43%

Lineage Cell Therapeutics, Inc. earnings per share and revenue

On May 12, 2026, LCTX reported earnings of -0.03 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -47.06% surprise. Revenue reached 1.73 million, compared to an expected 3.67 million, with a -53.04% difference. The market reacted with a -3.76% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 4.11 million USD, implying an decrease of -33.33% EPS, and increase of 138.34% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, Lineage Cell Therapeutics, Inc. reported EPS of -$0.03, missing estimates by -47.06%, and revenue of $1.73M, -53.04% below expectations.
The stock price moved down -3.76%, changed from $1.33 before the earnings release to $1.28 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 7 analysts, Lineage Cell Therapeutics, Inc. is expected to report EPS of -$0.02 and revenue of $4.11M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement